65894-76-0;EINECS 265-967-5;96424-97-4;1-Phenyl-1,2-propanedione-2-(O-ethoxycarboxy)oxime;1,2-Propanedione, 1-phenyl-, 2-(O-(ethoxycarbonyl)oxime);O-(Ethoxycarbonyl)-N-(1-methyl-2-oxo-2-phenylethylidene)hydroxylamine 

Sulprostone;Nalador;Sulprostonum [INN-Latin];Sulprostona [INN-Spanish];SHB 286;EINECS 262-173-0;CP 34089;CP-34089;ZK 57671;ZK-57671;60325-46-4;16-Phenoxy-omega-17,18,19,20-tetranor pge-2 methylsulfonylamide;16-Phenoxy-17,18,19,20 tetranor prostaglandin E(sub 2) methyl sulfonylamide;16-Phenoxy-omega-17,18,19,20-tetranor prostaglandin E2 methylsulfonylamide;(Z)-7-((1R,2R,3R)-3-Hydroxy-2-((E)-(3R)-(3-hydroxy-4-phenoxy-1-butenyl))-5-oxocyclopentyl)-N-(methylsulfonyl)-5-heptenamide;5-Heptenamide, 7-(3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl)-N-(methylsulfonyl)-, (1R-(1alpha(Z),2beta(1E,3R*),3alpha))-;sulproston;Sulprostona;Sulprostonum;34.089 Pfizer;Sulprostone (USAN/INN);Sulprostone [USAN:INN];AC1NSM49;UNII-501Q5EQ1GM;S8692_SIGMA;C23H31NO7S;SHB-286;MolPort-003-959-625;96420-78-9 (unknown MF);NCGC00165899-01;LS-74543;16-phenoxytetranor-PGE2 methylsulfonylamide;CP-34,089;ZK 57 671;D02725;16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methylsulfonylamide;(5Z,11alpha,13E,15R)--11,15-Dihydroxy-9-oxo-16-phenoxy-17,18,19,20-tetranorprosta-5,13-dienoic acid methane sulfonamide;(Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]-N-methylsulfonylhept-5-enamide;5-Heptenamide, 7-(3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl)-N-(methylsulfonyl)-, (1R-(1-alpha(Z),2-beta(1E,3R*),3-alpha))-;5-Heptenamide, 7-(3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl)-N-(methylsulfonyl)-, (1R-(1a(Z),2b(1E,3R*),3a))-;5Z,13E-18R,11R,12R,15R- dihydroxy-9-oxo-16-phenoxy-17,18,19,20-tetranor- 5,13-prostadienoic acid methylsulfonylamide